Cargando…
Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer
PURPOSE: Sequential drug treatments in metastatic breast cancer (MBC) are disparate. Clinical trial data includes limited reporting of treatment context, primarily including the number of prior therapies. This study evaluates the relationship between prior treatment time, prior lines of treatment, a...
Autores principales: | Rocque, Gabrielle B., Gilbert, Aidan, Williams, Courtney P., Kenzik, Kelly M., Nakhmani, Arie, Kandhare, Pravinkumar G., Bhatia, Smita, Burkard, Mark E., Azuero, Andres |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444642/ https://www.ncbi.nlm.nih.gov/pubmed/32479187 http://dx.doi.org/10.1200/CCI.20.00008 |
Ejemplares similares
-
Health care‐related time costs in patients with metastatic breast cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2020) -
Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
por: Franks, Jeffrey, et al.
Publicado: (2022) -
Healthy lifestyle discussions between healthcare providers and older cancer survivors: Data from 12 cancer centers in the Southeastern United States
por: Halilova, Karina I., et al.
Publicado: (2019) -
Assessment of Sarcopenia Measures, Survival, and Disability in Older Adults Before and After Diagnosis With Cancer
por: Williams, Grant R., et al.
Publicado: (2020) -
Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)